Upcoming Webinars

Switch to Calendar View

• BBANYS Oct 8, 2025 Webinar - Adverse Outcomes of Blood Transfusions: Making the Case for Transfusion Avoidance in Modern Medical Practice

  • When
    Wednesday, October 08, 2025
  •  
    3:00 PM - 4:00 PM
  • Location
    Online
  • Spaces left
    73

  Register

  Wednesday, October 8, 2025 / 3:00 PM - 4:00 PM EDT

  Topic:
  Adverse Outcomes of Blood Transfusions: Making the Case for Transfusion Avoidance in Modern Medical Practice
  
  

  Speaker:
  Mark T. Friedman, DO
  Clinical Associate Professor of Pathology
  Medical Director, Transfusion Service
  NYU Langone Health, NYU Grossman Long Island School of Medicine
  

  Speaker Bio:
  Dr. Mark Friedman is a Clinical Associate Professor and Medical Director of Transfusion Services at NYU Langone Health, NYU Grossman Long Island School of Medicine in Mineola, NY. He has been in practice for nearly 30 years and has taught, published extensively, and lectured in the area of patient blood management. He is a past president of BBANYS and currently serves as the BBANYS Newsletter Editor. He also is currently serving as the AABB Chair of the TSO/PBM Subsection.
  

  Abstract:
  

  Historically, transfusion risks were focused on transmissible diseases, especially hepatitis B and non-A-non-B hepatitis transmission (later identified as hepatitis C), which carried up to a 10% risk in the 1960’s and early 1970’s, and HIV after its emergence in the 1980’s. Although vigilance must be maintained in keeping these transmissible diseases and others (for example, West Nile virus and babesiosis) out of the blood supply, much of the focus has shifted to reducing non-transmissible disease risks, including mistransfusion of ABO incompatible blood, transfusion-related acute lung injury (TRALI), transfusion-associated circulatory overload (TACO), and platelet component bacterial contamination, among others. Yet, beyond even these recognized risks, transfusions are associated with thromboembolic complications (acute myocardial infarction and stroke), immunomodulatory effects (with increased risk of perioperative infections), and increased length of hospital stay, as evidenced by data from the Western Australia Patient Blood Management Program (PBM). As a result, the World Health Organization (WHO) has urgently called for global implementation of PBM, evidence-based strategies to conserve patients’ own blood and reduce the need for blood transfusions, in its October 2021 Policy Brief.
  
  Objectives:

  At the end of this session, the learner will be able to:

  1. Recognize historical transfusion risks, such as hepatitis and HIV, in the current context.
  2. Explain the transition of transfusion risk reduction from transmissible diseases to non-transmissible disease risks.
  3. Analyze the case for transfusion avoidance in transfusion risk reduction.

  Disclosures:
  

  None
  
  Pricing:

  • Members: FREE (Registration is required.)
  • Non-Members: $45 per session & $130 entire series
  • Institutions: $75 per session & $200 entire series

  To receive member pricing, be sure to sign in.
  
  View our calendar of upcoming events, including monthly webinars through December in our Fall Webinar Series, a special 9/17 webinar featuring our 2025 Annual Meeting poster winners, and our quarterly journal club!
  www.bbanys.org/events

  Show details
• BBANYS Nov 12, 2025 Webinar - Targeting FcRn in Hemolytic Disease of the Fetus and Newborn (HDFN)

  • When
    Wednesday, November 12, 2025
  •  
    3:00 PM - 4:00 PM
  • Location
    Online
  • Spaces left
    95

  Register

  Wednesday, November 12, 2025 / 3:00 PM - 4:00 PM EST

  Topic:
  Targeting FcRn in Hemolytic Disease of the Fetus and Newborn (HDFN)
  
  

  Speaker:
  Krystalyn E. Hudson
  Associate Professor of Pathology and Cell Biology, Co-Director of the Laboratory of Transfusion Biology
  Columbia University

  Speaker Bio:
  Dr. Krystalyn E. Hudson is an Associate Professor at Columbia University and Co-Director of the Laboratory of Transfusion Biology. She received her PhD from Emory University and completed her postdoctoral fellowship at Scripps Research Institute. Dr. Hudson’s NIH funded research focuses on immune responses to red blood cells (RBCs), which is relevant for transfusion medicine, pregnancy, and transplantation.

  Abstract:
  

  Hemolytic disease of the fetus and newborn (HDFN) arises when maternal IgG alloantibodies cross the placenta and target fetal red blood cells (RBCs), leading to their destruction and/or suppression. While anti-D alloantibodies are the most common cause—and can be prevented with anti-D immunoglobulin prophylaxis—HDFN can also result from other alloantibodies, such as those directed against the Kell blood group system, for which no approved prophylactic therapies currently exist.

  An emerging therapeutic approach for HDFN involves targeting the neonatal Fc Receptor (FcRn), a key regulator of IgG homeostasis and transplacental IgG transfer. FcRn protects IgG from lysosomal degradation and mediates its transport across epithelial barriers, including the placenta. Inhibiting FcRn accelerates IgG degradation and may reduce maternal IgG antibody from reaching the fetus, thereby attenuating HDFN severity. This presentation will review HDFN and discuss the current clinical landscape of FcRn-targeted therapies in HDFN.

  Objectives:
  
  At the end of this session, the learner will be able to:

  1. Describe HDFN
     
  2. Explain potential anti-D mechanisms
     
  3. Discuss the potential benefits and risks of targeting FcRn
     

  Disclosures:
  

  None
  
  Pricing:

  • Members: FREE (Registration is required.)
  • Non-Members: $45 per session & $130 entire series
  • Institutions: $75 per session & $200 entire series

  To receive member pricing, be sure to sign in.

  Show details
• BBANYS Dec 10, 2025 Webinar - IgA Deficiency: To Wash or Not

  • When
    Wednesday, December 10, 2025
  •  
    3:00 PM - 4:00 PM
  • Location
    Online
  • Spaces left
    95

  Register

  Wednesday, December 10, 2025 / 3:00 PM - 4:00 PM EST

  Topic:
  IgA Deficiency: To Wash or Not
  
  

  Speaker:
  Victoria Costa, MD
  Assistant Medical Director of Blood Bank
  NYU Langone Health Tisch Hospital
  

  Speaker Bio:
  Dr. Costa is currently Assistant Medical Director of the Blood Bank at NYU Langone Health Tisch Hospital, Clinical Assistant Professor in the Department of Pathology at NYU Grossman School of Medicine, Associate Program Director for the Clinical Pathology Residency Program and Medical Director of the 34th St and 38th St Clinical Laboratories at NYU Langone Health Perlmutter Cancer Center. She completed her medical education at The George Washington University, pathology residency at New York Presbyterian/Weill Cornell Medical Center, and transfusion medicine fellowship at Johns Hopkins Hospital. She is passionate about education and quality improvement efforts.

  Abstract:
  

  This webinar will review IgA deficiency, its diagnosis and management from the transfusion medicine perspective and ongoing areas of research.

  Objectives:
  
  At the end of this session, the learner will be able to:

  1. Define IgA deficiency and understand its relevance to transfusion medicine
  2. Understand how to provide transfusion support for those with IgA deficiency
     
  3. Learn about ongoing areas of research
     

  Disclosures:
  

  None
  
  Pricing:

  • Members: FREE (Registration is required.)
  • Non-Members: $45 per session & $130 entire series
  • Institutions: $75 per session & $200 entire series

  To receive member pricing, be sure to sign in.

  Show details